Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML-Reference-Cited by-同舟云学术

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Meyer Jan-Erik¹,Loff Simon¹,Dietrich Josephine¹,Spehr Johannes¹,Jurado Jiménez Gabriel¹,von Bonin Malte²,Ehninger Gerhard¹,Cartellieri Marc¹,Ehninger Armin¹

Affiliation:

1. GEMoaB GmbH, Dresden, Germany

2. Division of Hematology, Oncology and Stem Cell Transplantation, Medical Clinic I, Department of Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.1945804

Reference69 articles.

1. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

2. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

3. Recent developments in immunotherapy of acute myeloid leukemia

4. The myth of the second remission of acute leukemia in the adult

5. Reduced-Intensity Hematopoietic Stem Cell Transplants for Malignancies: Harnessing the Graft-Versus-Tumor Effect

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. UniCAR T-Cell Potency—A Matter of Affinity between Adaptor Molecules and Adaptor CAR T-Cells?;International Journal of Molecular Sciences;2024-06-30

2. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies;Frontiers in Immunology;2024-06-03

3. Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells;Cancer Immunology Research;2024-05-30

4. CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects;Journal of Clinical Medicine;2024-05-29

5. Transcriptional reprogramming via signaling domains of CD2, CD28, and 4-1BB;iScience;2024-03